|
Originally published In Press as doi:10.1074/jbc.M206595200 on August 16, 2002
J. Biol. Chem., Vol. 277, Issue 43, 41259-41267, October 25, 2002
Repression of DAX-1 and Induction of SF-1 Expression
TWO MECHANISMS CONTRIBUTING TO THE ACTIVATION OF ALDOSTERONE
BIOSYNTHESIS IN ADRENAL GLOMERULOSA CELLS*
Hanan
Osman,
Claire
Murigande,
Anne
Nadakal, and
Alessandro M.
Capponi
From the Division of Endocrinology and Diabetology, University
Hospital, CH-111 Geneva 14, Switzerland
Received for publication, July 3, 2002, and in revised form, August 6, 2002
 |
ABSTRACT |
Angiotensin II (Ang II) and adrenocorticotropic
hormone stimulate aldosterone biosynthesis in the zona glomerulosa of
the adrenal cortex through induction of the expression of the
steroidogenic acute regulatory (StAR) protein, which promotes
intramitochondrial cholesterol transfer. To understand the mechanism of
this induction of the StAR protein, we have examined the effect
of Ang II and forskolin, a mimicker of adrenocorticotropic hormone
action, on two transcription factors known to modulate StAR
gene expression in opposite ways, DAX-1 and SF-1, in bovine
adrenal glomerulosa cells in primary culture. Ang II markedly inhibited
DAX-1 protein expression in a time- and concentration-dependent
manner (to 38.7 ± 12.9% of controls at 3 nM after
6 h, p < 0.01), an effect that required de
novo protein synthesis and ERK2/1 activation. This effect was
associated with a concomitant decrease in DAX-1 mRNA and an
increase in mitochondrial StAR protein levels. Similarly, forskolin
dramatically repressed DAX-1 protein and mRNA expression (to
19.6 ± 1.8 and 50.3 ± 4.7% of controls, respectively,
p < 0.01). Neither Ang II nor forskolin affected
DAX-1 protein and mRNA stability. The aldosterone response to Ang
II was markedly reduced (to 59 ± 4% of controls,
p < 0.01) in transiently transfected cells
overexpressing DAX-1. Whereas Ang II was without effect on SF-1
expression, forskolin significantly increased SF-1 protein and mRNA
levels in a cycloheximide-sensitive manner (to 167.4 ± 16.6 and
173.1 ± 25.1% of controls after 6 h, respectively, p < 0.01). These results demonstrate that the balance
between repressor and inducer function of DAX-1 and SF-1 are of
critical importance in the regulation of adrenal aldosterone biosynthesis.
 |
INTRODUCTION |
The biosynthesis of aldosterone, the main mineralocorticoid
hormone, in the zona glomerulosa cells of the adrenal cortex is placed
under the control of three principal physiological factors, the
octapeptide hormone, angiotensin II (Ang
II),1 extracellular potassium
(K+), and adrenocorticotropic hormone (ACTH) (1). Whereas
Ang II and K+ exert their effect by recruiting the calcium
messenger system in glomerulosa cells (2, 3), ACTH acts mainly by
activating adenylyl cyclase and generating cAMP as an intracellular
messenger (4). In the cascade of subsequent events leading to the final production of aldosterone, the regulated, rate-limiting step is the
transfer of cholesterol from the relatively cholesterol-rich outer
mitochondrial membrane to the cholesterol-poor inner mitochondrial membrane (5). Cholesterol is then converted to pregnenolone by the
cytochrome P450 side chain cleavage enzyme (P450scc).
In all steroidogenic tissues, intramitochondrial cholesterol transfer
is facilitated by the steroidogenic acute regulatory (StAR) protein
(6). In the adrenal zona glomerulosa cell, the expression of the StAR
protein is rapidly increased by factors that activate mineralocorticoid
biosynthesis. Indeed, Ang II and ACTH have been shown to stimulate StAR
mRNA and StAR protein expression and to concomitantly increase
aldosterone production in bovine zona glomerulosa cells (7, 8).
Moreover, in human H295R adrenocortical carcinoma cells, which bear
only very few ACTH receptors, challenge with cAMP analogs, used to
mimic adenylyl cyclase activation, Ang II, or K+, leads to
StAR mRNA and protein expression (9, 10). Whereas the initial
signal transduction mechanisms mediating the steroidogenic action of
these activators of aldosterone biosynthesis are well characterized
(3), the events occurring downstream of Ca2+ or cAMP signal
generation and leading to the induction of StAR protein expression are
poorly understood.
No consensus cAMP response element has been found in the
~3.6-kilobase 5'-flanking region of the mouse, rat, human, porcine, and bovine StAR gene (11). In contrast, in all species,
several putative binding sites for steroidogenic factor-1 (SF-1), also called Ad4BP, are present in the StAR gene promoter (10,
12-16). The number and localization of these binding sites vary from
one species to the other. SF-1 is a nuclear transcription factor that was first identified in adrenal cortical cells (17). The orphan nuclear
receptor SF-1 plays a critical role in adrenal and gonadal differentiation, development, and function (18). Furthermore, SF-1 has
also been shown to regulate the expression of genes encoding cytochrome
P450 hydroxylases and to efficiently transactivate the StAR
gene in transient transfection assays in various cell types (13, 15,
16, 19). Although the extent of SF-1 involvement in the regulation of
StAR gene expression may present species- and cell
type-dependent differences (20), it appears that activation of the cAMP-signaling pathway leads to increased phosphorylation (21)
and/or expression (22) of SF-1 protein.
In addition to response elements for SF-1, the StAR gene
promoter also bears a binding site for another orphan member of the nuclear receptor superfamily, DAX-1 (dosage-sensitive sex
reversal adrenal hypoplasia congenita critical
region on the X chromosome, gene 1) (23, 24).
DAX-1 has been shown to act as a powerful repressor of StAR
gene expression. Indeed, overexpression of DAX-1 in Y-1 mouse adrenal
tumor cells inhibits steroid synthesis, and DAX-1 represses both basal
and cAMP-induced StAR promoter activity by binding to DNA
hairpin secondary structures on the StAR gene promoter or to
the SF-1 protein itself (25). Furthermore, overexpression of DAX-1 in
Y-1 adrenocortical cells impairs basal and cAMP-stimulated steroid
production (26). Conversely, cAMP down-regulates DAX-1 expression in
cultured rat Sertoli cells (26). Finally, SF-1 and DAX-1 are
co-localized in various endocrine and steroidogenic tissues, suggesting
that these two nuclear proteins may be linked in function.
Because Ang II and ACTH stimulate StAR protein expression, the present
study was undertaken to investigate whether the mechanism of this
response involves a modulation of DAX-1 and SF-1 expression. We report
here that both Ang II, a calcium mobilizing hormone, and forskolin,
used as a mimicker of ACTH action to generate a pure cAMP signal,
markedly inhibit DAX-1 expression at the mRNA and protein level. We
also show that forskolin significantly increases SF-1 expression. This
study provides evidence that the removal of the suppressor effect of
DAX-1 on StAR expression is an important mechanism through which
activators of aldosterone biosynthesis increase StAR expression.
 |
EXPERIMENTAL PROCEDURES |
Bovine Adrenal Zona Glomerulosa Cell Culture and
Treatments--
Bovine adrenal glands were obtained from a local
slaughterhouse. Zona glomerulosa cells were prepared by enzymatic
dispersion with dispase and purified on Percoll density gradients as
previously reported (27). Primary cultures of purified glomerulosa
cells were maintained in Dulbecco's modified Eagle's medium as
described in detail elsewhere (27). The cells were grown on 6-well
tissue culture plates (3 × 106 cells/well) and kept
in serum-free medium for 24 h before experiments, which were
performed on the third day of culture. Cells were then washed and
incubated at 37 °C in serum-free medium containing various agents
for varying periods of time as appropriate. At the end of the
incubation period, the media were collected, and cells were processed
for protein or total RNA extraction as described hereafter.
Determination of Aldosterone Production--
Aldosterone content
in incubation media was measured by direct radioimmunoassay using a
commercially available kit (Diagnostic Systems Laboratories, Webster,
TX). Aldosterone production was normalized and expressed per milligram
of cellular protein.
Western Blot Analysis--
For the determination of protein
expression levels, bovine glomerulosa cells were washed twice in
ice-cold phosphate saline buffer (PBS) and lysed in PBS containing 1%
(v/v) Triton X-100, 0.1% (w/v) sodium dodecyl sulfate, 0.5% (w/v)
deoxycholate, 1 mM phenylmethylsulfonyl fluoride, and 1 µg/ml leupeptine. The cell debris were removed by centrifugation at
20,000 × g at 4 °C for 15 min, and supernatants
were used as cell lysates. Proteins were quantified using a protein
microassay (Bio-Rad). Equal amounts of protein (20 µg) were resolved
by 12% SDS-polyacrylamide gel electrophoresis and transferred onto
polyvinylidene difluoride membranes. Western blot analysis of DAX-1 and
SF-1 proteins was carried out with a mouse monoclonal antiserum
directed against DAX-1 (kindly provided by Dr. Enzo Lalli, Strasbourg,
France) or a rabbit polyclonal antiserum to Ad4BP/SF-1 (kindly supplied by Dr. Ken Morohashi, University of Tsukuba, Japan). Mitochondrial StAR
protein levels were determined by Western blot as previously described
(8). Immunoreactive proteins were visualized by the enhanced
chemiluminescence method (ECL, Amersham Biosciences). Band intensity
was quantified with a Molecular Dynamics Computing Densitometer.
Transient Transfection of Bovine Glomerulosa Cells with DAX-1
cDNA--
For transfection experiments, 800,000 bovine glomerulosa
cells were seeded in 60-mm Petri dishes. Cells were transfected using Effectene transfection reagent (Qiagen, Basel, Switzerland) according to the manufacturer's instructions. One µg of pBKCMV-hDAX-1 encoding the human DAX-1 protein was introduced into cells at a DNA:Effectene ratio of 1:50. The same conditions were used with the empty vector pBKCMV for mock-transfected cells. Cells were incubated with the transfection complexes for 8 h then washed twice with phosphate saline buffer and incubated for 48 h in fresh medium supplemented with serum. In separate experiments with pBKCMV-GFP encoding the green
fluorescent protein we observed that the transfection efficacy amounted
to 35-40% under the above conditions (data not shown). Cells were
then challenged with Ang II, and DAX-1 protein levels were determined
as described.
Cloning of Bovine DAX-1 from Zona Glomerulosa Cells--
Total
cellular RNA was isolated from bovine glomerulosa cells using the SV
Total RNA Isolation system (Promega, Zurich, Switzerland) according to
the manufacturer's instructions. Total RNA (500 ng) was
reverse-transcribed and amplified using the Access RT-PCR system
(Promega). A fragment of bovine DAX-1 cDNA (214 base pairs) was
amplified using human DAX-1 primers (5'-AGGGGACCGTGCTCTTTAAC-3' forward
and 5'-ATGATGGGCCTGAAG AACAG-3' reverse). Primers corresponded to
positions +1145-1164 and 1339-1358 of the human DAX-1
(NCBI/GenBankTM accession number NM_000457). The PCR
product was purified from a 1% agarose gel, cloned into pGEM®-T Easy
vector (Promega), and amplified in JM 109 competent cells. The plasmid
insert was sequenced by automatic sequencing using the DyEnamics
Terminator sequencing kit (Amersham Biosciences) and Applied Biosystem
3100 sequencer.
Reverse Transcription-Polymerase Chain Reaction--
RT-PCR was
used to evaluate DAX-1 and SF-1 mRNA abundance in response to
various treatments. RT-PCR measurements of mRNA were performed
using Promega reagents and 500 ng of total RNA per reaction. Reverse
transcription with avian myeloblastosis virus RT (5 units/reaction, 48 °C for 30 min) primed with specific primers was followed by PCR
using Tfl DNA polymerase (5 units/reaction) with the
following cycling parameters: denaturation for 5 min at 95 °C
followed by 30 and 25 cycles for DAX-1 and SF-1, respectively, of
95 °C for 1 min, 56 °C for 1 min, and 68 °C for 30 s and
a final extension at 68 °C for 10 min. The primers were bovine SF-1
(5'-GCAGAAGAAGGCACAGATTC-3' (forward) and 5'-TGGGTACTCAGACTTGATGG-3'
(reverse). Primers corresponded to positions +439-459 and 693-713 of
the bovine Ad4BP mRNA (NCBI/GenBankTM accession number
D13569). DAX-1 primers were as described above. To correct for
potential variations in RT-PCR efficiency, an internal control, a
fragment of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene
was co-amplified in each sample using as the sense primer
5'-ATGGTGAAGGTCGGAGTG-3' and as the antisense primer
5'-TGCAGAGATGATGACCCTC-3'. Primers corresponded to positions +82-99
and 426-444 of the human GAPDH (NCBI/GenBankTM accession
number NM_002046). The combination of GAPDH and SF-1 primers yielded
two products corresponding to 362 and 274 bp for GAPDH and SF-1,
respectively, and that of GAPDH and DAX-1 yielded two products
corresponding to 362 and 214 bp for GAPDH and DAX-1, respectively. Ten
microliters of the PCR product were separated by electrophoresis on
ethidium bromide-stained 1.3% agarose gels. The intensity of each band
was normalized to the intensity of the corresponding GAPDH band. Bands
were quantified by image analysis using the NIH Image 1.23 software
(rsb.info.nih.gov/nih-image/download.html). All amplified sequences
were confirmed by automatic sequencing. Plots of product amount
versus cycle number were linear, confirming that all
reactions were run in the exponential part of the progress curve.
Data Deposition--
The partial sequence of bovine DAX-1 has
been deposited in the GenBankTM data base (Bethesda, MD)
under accession number AF421373.
Data Bank Search--
The nucleic acid and derived amino acid
sequences of DAX-1 cDNA were compared with known sequences provided
by the National Center for Biotechnology Information (Bethesda, MD)
using Blast searches. Comparison of nucleotide and deduced amino acid
sequences were performed using ClustalW.
Statistical Analysis--
The data presented are the mean ± S.E. The statistical significance of differences between treatments
was determined by one-way analysis of variance and Fisher's protected
least significant difference test. Values of p < 0.05 or less were considered statistically significant.
 |
RESULTS |
Angiotensin II Inhibits DAX-1 Protein Expression--
DAX-1
protein levels were high in unstimulated bovine adrenal glomerulosa
cells. When cells were treated with Ang II for 6 h, a significant,
concentration-dependent inhibition of DAX-1 protein
expression was observed between 0.1 and 10 nM Ang II, as
determined by Western blot analysis. Maximal inhibition (to 38.7 ± 12.9% of controls, n = 3-9, p < 0.01) was achieved with 3 nM Ang II (Fig.
1, A and B).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 1.
Angiotensin II inhibits DAX-1 protein
expression in adrenal glomerulosa cells. Bovine glomerulosa cells
were stimulated with increasing concentrations of Ang II (0-10
nM) for 6 h. Equal amounts (20 µg) of whole cell
extracts were used in each lane and analyzed by 12% SDS-PAGE. DAX-1
protein was detected by Western blot. A, Western blot of
DAX-1 from a representative experiment. B, densitometric
analysis of DAX-1 protein expression shown as a percentage of control
(0 nM Ang II). Values represent the mean ± S.E. of
3-9 independent experiments. C, Western blot of
mitochondrial StAR protein. D, aldosterone production in the
culture medium. Values represent the mean ± S.E. of three
independent experiments performed in duplicate. **, significantly
different from control, p < 0.01.
|
|
Concomitantly, Ang II powerfully stimulated intramitochondrial StAR
protein accumulation (Fig. 1C) and aldosterone production (Fig. 1D) over the same range of concentrations. At 10 nM Ang II, aldosterone production into the medium was
increased by 71-fold (127.2 ± 19.4 pmol/mg of protein
versus 1.8 ± 0.26 pmol/mg in control cells,
n = 3, p < 0.01).
Kinetics of the Effect of Ang II on DAX-1 Protein
Expression--
To determine the kinetics of the inhibition of DAX-1
protein expression induced by Ang II, we stimulated glomerulosa cells with 10 nM Ang II for 0-6 h. As shown in Fig.
2, A and B, the inhibitory effect of Ang II was time-dependent, with DAX-1
protein levels reaching 61.5 ± 4.6% (n = 5, p < 0.01) and 40 ± 3.4% of controls
(n = 5, p < 0.01) after 4 and 6 h, respectively. No further decrease in DAX-1 protein expression was
observed thereafter (data not shown). The progressive inhibition
of DAX-1 protein expression was accompanied with a
time-dependent increase in aldosterone production from Ang
II-treated adrenal glomerulosa cells (Fig. 2C).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 2.
Kinetics of Ang II-inhibited DAX-1 protein
expression. Bovine glomerulosa cells were stimulated with 10 nM Ang II, and cells were harvested at the indicated times
(0-6 h). DAX-1 protein analysis was performed as described in the
legend of Fig. 1. A, Western blot of DAX-1 from a
representative experiment. CHX, cycloheximide. B,
densitometric analysis of DAX-1 protein expression shown as a
percentage of control (0 h). Values represent the mean ± S.E. of
five independent experiments. C, aldosterone production in
the culture. Values represent the mean ± S.E. of 3-5 independent
experiments performed in duplicate. **, significantly different from
control, p < 0.01.
|
|
Ang II-induced Inhibition of DAX-1 Protein Expression Requires
Protein Synthesis--
The inhibition of DAX-1 protein expression by
Ang II depended upon de novo protein synthesis. Indeed,
although glomerulosa cells stimulated with 10 nM Ang II for
6 h showed a significant decrease in DAX-1 protein levels (to
40.8 ± 2.6% of controls, n = 3, p < 0.01), simultaneous treatment with cycloheximide,
a protein translation inhibitor, abolished the Ang II-induced
inhibition of DAX-1 protein expression (Fig.
3, A and B).
Cycloheximide also completely abolished the aldosterone response to Ang
II, as previously reported by others (28) (Fig. 3C).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 3.
The inhibitory effect of Ang II on DAX-1
protein expression requires de novo protein synthesis.
Adrenal glomerulosa cells were stimulated for 6 h in the
absence or in the presence of 10 nM Ang II and
cycloheximide (CHX; 50 µM). DAX-1 protein
analysis was performed as described in the legend of Fig. 1.
A, Western blot of DAX-1 from a representative experiment.
B, densitometric analysis of DAX-1 protein expression shown
as a percentage of control. Values represent the mean ± S.E. of
three independent experiments. C, aldosterone production in
the culture medium. Values represent the mean ± S.E. of three
independent experiments performed in duplicate. **, significantly
different from control, p < 0.01.
|
|
Involvement of ERK2/1 Activation in Ang II-induced
Repression of DAX-1--
Ang II is known to activate ERK2/1 in bovine
adrenal glomerulosa cells (29). To determine whether inhibition of
DAX-1 protein expression by Ang II is mediated by the mitogen-activated
protein kinase pathway, we stimulated cells with Ang II alone or in
combination with U0126 (Biomol, Plymouth Meeting, PA), an inhibitor of
MEK-1, the kinase that phosphorylates and activates ERK2/1. As shown in
Fig. 4, A and B,
the inhibitory effect of Ang II on DAX-1 expression was completely
abolished in the presence of U0126. In contrast, the p38
mitogen-activated protein kinase inhibitor, SB203580, did not affect
Ang II action (data not shown).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 4.
Involvement of ERK2/1 in Ang II-induced
inhibition of DAX-1 protein and mRNA expression. Adrenal
glomerulosa cells were stimulated for 6 h with 10 nM
Ang II alone or in combination with 10 µM U0126. DAX-1
protein analysis was performed as described in the legend of Fig. 1.
RT-PCR was done as described under "Experimental Procedures."
A, Western blot of DAX-1 from a representative experiment.
B, densitometric analysis of DAX-1 protein expression shown
as a percentage of control. C, representative ethidium
bromide staining of an agarose gel after 30 cycles of RT-PCR.
D, densitometric analysis of DAX-1 mRNA shown as a
percentage of untreated control after normalization for GAPDH mRNA.
E, aldosterone production in the culture medium. Values
represent the mean ± S.E. of three independent experiments. **,
significantly different from control, p < 0.01; ##,
significantly different from Ang II, p < 0.01
|
|
To determine whether Ang II exerts its inhibitory effect directly on
DAX-1 mRNA expression, we stimulated glomerulosa cells for 6 h
with 10 nM Ang II alone or in combination with 10 µM U0126, and DAX-1 mRNA levels were then determined
by semi-quantitative RT-PCR. The results shown in Fig. 4, C
and D, indicate that Ang II treatment led to a significant
decrease in bovine DAX-1 mRNA levels (to 68.8 ± 4.3% of
controls, n = 4, p < 0.01). This
down-regulation of DAX-1 mRNA by Ang II was completely prevented by
the MEK-1 inhibitor U0126.
The involvement of ERK2/1 in the functional response to Ang II was also
observed at the level of steroid production. Indeed, as shown in Fig.
4E, two structurally unrelated MEK-1 inhibitors, U0126 and
PD98059 (Alexis Biochemicals, Läufelfingen, Switzerland), significantly reduced aldosterone production elicited by Ang II.
Forskolin Inhibits DAX-1 Protein and mRNA Expression--
We
next examined whether another inducer of StAR expression and
aldosterone production, forskolin, used as a mimicker of ACTH, which
mobilizes the cAMP messenger system, also affects DAX-1 expression. As
shown in Fig. 5, A and
B, treatment of adrenal glomerulosa cells with 25 µM forskolin for 6 h dramatically inhibited DAX-1
protein expression (to 19.6 ± 1.82% of controls,
n = 3, p < 0.001). As for Ang II,
inhibition of DAX-1 protein expression by forskolin was concentration-
and time-dependent (data not shown). Furthermore, the
inhibition of DAX-1 protein expression by forskolin was completely
prevented by cycloheximide. In contrast, the MEK-1 inhibitor, U0126,
had no effect on forskolin action. The inhibition of DAX-1 protein
expression provoked by forskolin was associated with a 56-fold increase
in aldosterone production (Fig. 5E).

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 5.
Forskolin inhibits DAX-1 protein and mRNA
expression in adrenal glomerulosa cells. Adrenal glomerulosa cells
were stimulated for 6 h with 25 µM forskolin
(FK) alone or in combination with 10 µM U0126
or 50 µM cycloheximide (CHX). DAX-1 protein
analysis and DAX-1 mRNA RT-PCR were performed as described in the
legends of Figs. 1 and 4. Ctrl, control. A,
Western blot of DAX-1 from a representative experiment. B,
densitometric analysis of DAX-1 protein expression shown as a
percentage of control. C, representative ethidium bromide
staining of an agarose gel after 30 cycles of RT-PCR. D,
densitometric analysis of DAX-1 mRNA shown as percentage of
untreated control after normalization for GAPDH mRNA. E,
aldosterone production in the culture medium. Values represent the
mean ± S.E. of three independent experiments. **, significantly
different from control, p < 0.01. Values represent the
mean ± S.E. of three independent experiments.
|
|
The inhibition of DAX-1 expression by forskolin was also observed at
the transcriptional level, as demonstrated in Fig. 5, C and
D. Indeed, in glomerulosa cells stimulated with forskolin, DAX-1 mRNA levels were decreased to 50.3 ± 4.7% of control
untreated cells (n = 3, p < 0.0.01).
This effect was not reversed by the MEK-1 inhibitor, U0126. Moreover,
actinomycin D did not affect the reduction of DAX-1 mRNA expression
elicited by forskolin (data not shown).
Ang II and Forskolin Do Not Affect DAX-1 Protein and mRNA
Degradation--
To determine whether Ang II and forskolin decreased
DAX-1 protein levels by accelerating its catabolism, we incubated
bovine glomerulosa cells for 6 h in the absence or presence of
either agonist and then followed DAX-1 protein levels under conditions of protein synthesis blockade. As shown in Fig.
6A, DAX-1 protein levels were
quite stable over time under basal conditions and in the absence of
cycloheximide. In contrast, when de novo protein synthesis
was prevented, the levels of DAX-1 protein decreased markedly with
time, with a half-life of ~6 h. Neither Ang II nor forskolin
accelerated this process (Fig. 6A).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 6.
Lack of effect of Ang II and forskolin of
DAX-1 protein and mRNA stability. Cells were treated for
6 h without (Control) or with Ang II (10 nM) or forskolin (FK; 25 µM), then
cycloheximide (CHX; A) or actinomycin D
(B) was added, and DAX protein or mRNA levels were
determined. Values represent the mean ± S.E. of 2-3 independent
experiments.
|
|
The inhibition of DAX-1 mRNA expression could result from changes
in transcription rate and/or in mRNA turnover. We therefore examined whether Ang II affected DAX-1 mRNA stability. Glomerulosa cells were treated for 6 h in the absence or presence of Ang II (10 nM), and then actinomycin D was added. After 6 h,
DAX-1 mRNA levels decayed to 45.2% of the zero time value in cells
treated with actinomycin D alone and to a similar value (53.4 ± 4.9%, n = 3, p < 0.01) in cells that
had been pretreated with Ang II (Fig. 6B). Similar results
were obtained with forskolin (data not shown).
Effect of Overexpression of DAX-1 on the Aldosterone Response to
Ang II--
The role of DAX-1 on the aldosterone response to Ang II
was confirmed in bovine glomerulosa cells that had been transiently transfected with DAX-1 cDNA. In cells transfected with the empty pBKCMV vector, Ang II induced a robust aldosterone production (Fig.
7, Mock). Although the
absolute aldosterone values were somewhat lower than in non-transfected
cells, possibly because of the transfection procedure itself, the fold
increase over basal was not significantly different (see, for example,
Figs. 1D, 3C, or 4C). This aldosterone
response was associated with the expected repression of DAX-1. In
contrast, in cells transiently transfected with pBKCMV-hDAX-1, which
expressed 20-30-fold higher levels of the DAX-1 protein, the
aldosterone response to Ang II was significantly reduced to 59.4 ± 4% of the response measured in mock-transfected cells
(n = 3, p < 0.01).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of DAX-1 overexpression on the
aldosterone response to Ang II. Cells were either mock-transfected
(Mock) or transfected with DAX-1 cDNA as described under
"Experimental Procedures." Cells were then challenged with Ang II
(10 nM) for 6 h, and DAX-1 protein levels
(top) and aldosterone production (bottom) were
determined thereafter. Values represent the mean ± S.E. of three
independent experiments. **, significantly different from
mock-transfected cells, p < 0.01.
|
|
Effects of Ang II and Forskolin on SF-1 Protein and
mRNA Expression--
Because the transcription factor SF-1 is
known to regulate StAR protein expression, we examined whether the
induction of StAR expression induced by both Ang II and forskolin
involves changes in SF-1 protein expression in adrenal glomerulosa
cells. As shown in Fig. 8, A
and B, a significant increase in SF-1 protein expression was
observed in cells stimulated for 6 h with forskolin (167.4 ± 16.6% of controls, n = 7, p < 0.001),
whereas Ang II had no effect. The forskolin-induced increase in SF-1
protein expression was blocked by cycloheximide.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 8.
SF-1 protein and mRNA expression under
Ang II and forskolin treatment in bovine adrenal glomerulosa
cells. Adrenal glomerulosa cells were treated for 6 h with 10 nM Ang II or 25 µM forskolin (FK)
in the presence or in the absence of 50 µM cycloheximide
(CHX) or of 1 µg/ml actinomycin D. Western blotting of
SF-1 protein and RT-PCR of SF-1 mRNA were performed as described
under "Experimental Procedures." A, Western blot of SF-1
from a representative experiment. B, densitometric analysis
of SF-1 protein expression shown as a percentage of control.
C, representative ethidium bromide staining of an agarose
gel after 30 cycles of RT-PCR. Ctrl, control. D,
densitometric analysis of SF-1 mRNA shown as percentage of
untreated control after normalization for GAPDH mRNA. Values
represent the mean ± S.E. of three independent experiments. **,
significantly different from control, p < 0.01.
|
|
We next examined whether forskolin and Ang II affected SF-1 mRNA
expression. Bovine glomerulosa cells were stimulated for 6 h with
10 nM Ang II or 25 µM forskolin, and SF-1
mRNA levels were then determined by semi-quantitative RT-PCR. The
results shown in Fig. 8, C and D, indicate that
forskolin treatment led to a significant increase in bovine SF-1
mRNA levels (to 173.1 ± 25.1% of controls, n = 5, p < 0.05). In contrast, Ang II had no significant
effect on SF-1 mRNA expression. The forskolin-induced increase in
SF-1 mRNA expression was almost completely abolished by actinomycin
D (Fig. 8, C and D), suggesting a direct action of forskolin on SF-1 mRNA at the transcriptional level.
 |
DISCUSSION |
The present study was undertaken in an attempt to investigate the
mechanism of the known induction of StAR protein expression in adrenal
glomerulosa cells in response to two physiological activators of
aldosterone biosynthesis, the octapeptide hormone angiotensin II and
adrenocorticotropic hormone, ACTH (10, 30). We have focused our
attention on two orphan members of the nuclear receptor family of
transcription factors, DAX-1 and SF-1. Indeed, on one hand, DAX-1 has
been shown to repress StAR gene expression by binding to a
hairpin structure located in the StAR gene promoter and to
block steroidogenesis (25). On the other hand, multiple binding
elements for SF-1 have been reported in the 5'-flanking region of the
StAR gene and are required for maximal promoter activity
(4).
Two main conclusions can be drawn from the present work. 1) Ang II,
which recruits the calcium messenger signaling system (31), and
forskolin, used as a mimicker of ACTH action via cAMP generation, both
markedly repressed DAX-1 expression, and 2) forskolin significantly
increased the expression of SF-1. It is worth stressing that these
observations were obtained in bovine glomerulosa cells in primary
culture, expressing normal levels of only endogenous DAX-1 and SF-1,
rather than in artificial overexpression systems.
The inhibition of DAX-1 exerted by Ang II and forskolin was manifest at
both the protein and mRNA levels. In fact, although most studies
have focused on the developmental and tissular distribution of DAX-1
expression in various species (32, 33), on its mechanism of action (25,
34, 35), and on the incidence of mutations in the DAX-1 gene
on adrenal and reproductive functions (23, 24, 36, 37), information on
the regulation of DAX-1 expression in steroidogenic tissues is
practically non-existent. In our hands, the aldosterone response was
correlated with the extent of the repression of DAX-I, the highest
amounts of the mineralocorticoid being produced when DAX-1 protein
levels were the lowest.
In principle, two main mechanisms can account for the inhibition of
DAX-1 expression observed in response to Ang II and forskolin; they are
1) an inhibition of DAX-1 gene transcription and/or
translation, leading to reduced mRNA and protein levels, and 2) a
decrease in DAX-1 mRNA and/or protein stability. Our data indicate
that the latter mechanism is much less likely to occur. Indeed, neither Ang II nor forskolin accelerated the decay rate of DAX-1 mRNA or
protein under conditions of blockade of transcription with actinomycin
or blockade of protein translation with cycloheximide; a half-life of
~6 h was measured for the DAX-1 protein whether the agonists were
present or not. Therefore, a more likely mechanism should be the
induction by Ang II and forskolin of a repressor protein, which blocks
DAX-1 gene transcription. Consistent with this hypothesis, the
repression exerted by Ang II and forskolin was abolished under
conditions of protein synthesis inhibition.
A number of studies suggest that the mitogen-activated protein kinase
cascade is involved in the regulation of steroidogenesis. For example,
ERK2/1 activation mediates the stimulation of steroid production in
porcine (35), murine (38), and human (39) ovarian granulosa cells. In
bovine adrenal glomerulosa cells, Ang II stimulates ERK2/1 (p42/44)
activity via protein kinase C and Ras/Raf-1 kinase (29). Whether this
activation contributes only to the trophic effect of Ang II on adrenal
cells or also to the steroidogenic response was not known. In the
present study, the ERK2/1-mediated inhibition of DAX-1 expression
induced by Ang II would suggest a major role for ERK2/1 in Ang
II-induced aldosterone production. In contrast, the role of ERK2/1 in
the activation of adrenal steroidogenesis by ACTH or forskolin is controversial. Thus, forskolin was found to increase StAR expression and steroidogenesis in Y1 mouse adrenocortical tumor cells and to
activate ERK2/1 (21). In contrast, in bovine fasciculata and rat
glomerulosa cells, ACTH treatment did not lead to p42/44 mitogen-activated protein kinase (ERK2/1) activation (40, 41). In
agreement with the latter reports, in our hands the massive inhibition
of DAX-1 expression elicited by forskolin was insensitive to two
unrelated inhibitors of p42/44 activation, a finding that rules out an
involvement of ERK2/1 in the steroidogenic response to cAMP.
The role of DAX-1 in the steroidogenic response to Ang II was
corroborated in cells overexpressing DAX-1. Indeed, Ang II-induced aldosterone production was markedly reduced in cells expressing 20-30-fold higher levels of DAX-1. This finding is in agreement with a
previous report showing that steroid production is impaired in Y-1
adrenocortical cells expressing DAX-1 (34) and, to the contrary, with
the demonstration that mice lacking DAX-1 show an increased adrenal
responsiveness to ACTH (42). In Y-1 cells expressing DAX-1, the
steroidogenic response to forskolin was completely suppressed (34),
whereas in our hands, the aldosterone response to Ang II was highly
significantly but incompletely decreased in bovine glomerulosa cells
overexpressing DAX-1. Because the transfection efficacy amounted to
only 35-40% in these cells, it is likely that, in fact, the extent of
inhibition in the transfected cells was somewhat underestimated.
Whether blockade of aldosterone synthesis in cells overexpressing DAX-1
is actually complete is presently unknown. In fact, previous work from
our laboratory would tend to suggest that this is not the case. Indeed,
we have shown that Ang II also promotes aldosterone biosynthesis
through non-genomic mechanisms via the calcium messenger system, such as intramitochondrial cholesterol transfer (7, 31), a process that
could explain the residual aldosterone response to the hormone in the
presence of high levels of DAX-1.
The two activators of mineralocorticoid biosynthesis also markedly
differed in their effect on SF-1 expression. Indeed, on one hand,
forskolin significantly increased SF-1 mRNA and protein expression.
This result is consistent with a previous study showing that forskolin
induces an increase in SF-1 protein expression in granulosa-derived
cell lines (43). On the other hand, Ang II was without effect.
The StAR promoter is known to be responsive to stimulation by cAMP
despite the fact that it lacks a consensus cAMP response element (14,
15). Multiple SF-1 binding sites are present in the StAR promoter (13)
and SF-1, which is known to positively regulate StAR expression (12,
13, 15, 16, 19, 44, 45), mediates cAMP responsiveness (13, 15).
In addition, SF-1-mediated StAR gene transcription has been
shown to be enhanced by phosphorylation of a single serine residue (Ser-203) located in the hinge region of the protein (46, 47). Ser-203
is a substrate for ERK2/1 in vitro and is critical for activation of SF-1 by multiple components of the mitogen-activated protein kinase pathway (46, 47). In Y1 adrenocortical cells, forskolin
stimulation leads to activation of ERK2/1 and phosphorylation of SF-1
(21), although it is not known whether this response is accompanied by
an increase in SF-1 protein expression. Our results in bovine
glomerulosa cells differ from those of the latter work in that we did
not observe an involvement of ERK2/1 activation in the repressor effect
of forskolin. In contrast, our data clearly demonstrate that forskolin
markedly increases SF-1 protein expression, a result that is also
compatible with an increase in the amount of phosphorylated SF-1.
In contrast to forskolin, Ang II had no effect on SF-1 expression. In
human H295R adrenocortical carcinoma cells, deletion analysis of the
StAR gene promoter has shown that Ang II and dibutyryl cAMP
activation of reporter gene expression requires the presence of one
critical SF-1 binding site located proximally to the transcriptional start site, within the 150 first bases (10, 13). No effect of Ang II or
forskolin on endogenous SF-1 protein expression or phosphorylation was
reported. The proximal SF-1 binding element overlaps with a hairpin
structure (nucleotides 61 to 27), which is a binding site for DAX-1
and mediates DAX-1-induced StAR gene repression (25). In
fact, DAX-1 is likely to act as a suppressor of SF-1-induced
transcription. Indeed, recent studies demonstrate a direct interaction
between DAX-1 and SF-1, potentially recruiting co-repressors such as
NcoR (nuclear receptor co-repressor) to the transcription factor
complex (48, 49). Our results demonstrating that Ang II and forskolin
block DAX-1 expression are, therefore, compatible with a model in which
binding of DAX-1 to the hairpin structure and/or heterodimer formation
between DAX-1 and SF-1 is prevented, the latter thus becoming able to
enhance StAR gene expression.
In summary, we have shown that two activators of aldosterone
biosynthesis in adrenal zona glomerulosa cells mobilizing distinct signaling pathways markedly lower the expression levels of DAX-1, a
known repressor of the StAR protein, which plays a crucial role in the
activation of steroidogenesis. Our studies provide the first evidence
that the balance between DAX-1 and SF-1 expression levels,
i.e. between repressor and inducer functions, may play a key
role in the fine tuning of the mineralocorticoid response. In view of
the specific distribution of these two transcription factors, this
mechanism may be of general relevance in all steroid-producing tissues.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF421373.
To whom correspondence should be addressed: Division of
Endocrinology and Diabetology, University Hospital, 24, rue
Micheli-du-Crest, CH-111 Geneva 14, Switzerland. Tel.: 41-22-372-93-62;
Fax: 41-22-372-93-29; E-mail:
alessandro.capponi@medecine.unige.ch.
Published, JBC Papers in Press, August 16, 2002, DOI 10.1074/jbc.M206595200
 |
ABBREVIATIONS |
The abbreviations used are:
Ang II, angiotensin
II;
ACTH, adrenocorticotropic hormone;
DAX-1, dosage-sensitive sex
reversal adrenal hypoplasia congenita critical region on the
X-chromosome, gene 1;
IOD, integrated optical density;
P450scc, cholesterol side chain cleavage cytochrome P450;
SF-1, steroidogenic factor-1;
StAR protein, steroidogenic acute
regulatory protein;
RT, reverse transcriptase;
MEK, mitogen-activated
protein kinase/extracellular signal-regulated kinase kinase;
ERK, extracellular signal-regulated kinase;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
 |
REFERENCES |
| 1.
|
Müller, J.
(1988)
Regulation of Aldosterone Biosynthesis
, Springer-Verlag, Berlin
|
| 2.
|
Capponi, A. M.,
Rossier, M. F.,
Davies, E.,
and Vallotton, M. B.
(1988)
J. Biol. Chem.
263,
16113-16117[Abstract/Free Full Text]
|
| 3.
|
Capponi, A. M.,
and Rossier, M. F.
(1996)
Curr. Opin. Endocrinol. Diabetes
3,
248-257
|
| 4.
|
Baukal, A. J.,
Hunyady, L.,
Catt, K. J.,
and Balla, T.
(1994)
J. Biol. Chem.
269,
24546-24549[Abstract/Free Full Text]
|
| 5.
|
Jefcoate, C. R.,
McNamara, B. C.,
Artemenko, I.,
and Yamazaki, T.
(1992)
J. Steroid Biochem. Mol. Biol.
43,
751-767[CrossRef]
|
| 6.
|
Stocco, D. M.,
and Clark, B. J.
(1996)
Endocr. Rev.
17,
221-244[Abstract/Free Full Text]
|
| 7.
|
Cherradi, N.,
Rossier, M. F.,
Vallotton, M. B,
Timberg, R.,
Friedberg, I.,
Orly, J.,
Wang, X. J.,
Stocco, D. M.,
and Capponi, A. M.
(1997)
J. Biol. Chem.
272,
7899-7907[Abstract/Free Full Text]
|
| 8.
|
Cherradi, N.,
Brandenburger, Y.,
Rossier, M. F.,
Vallotton, M. B.,
Stocco, D. M.,
and Capponi, A. M.
(1998)
Mol. Endocrinol.
12,
962-972[Abstract/Free Full Text]
|
| 9.
|
Clark, B. J.,
Pezzi, V.,
Stocco, D. M.,
and Rainey, W. E.
(1995)
Mol. Cell. Endocrinol.
115,
215-219[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Clark, B, J.,
and Combs, R.
(1999)
Endocrinology
140,
4390-4398[Abstract/Free Full Text]
|
| 11.
|
Christenson, L. K.,
and Strauss, J. F.
(2000)
Biochim. Biophys. Acta
1529,
175-187[Medline]
[Order article via Infotrieve]
|
| 12.
|
Sugawara, T.,
Kiriakidou, M.,
Mcallister, J. M.,
Holt, J. A.,
Arakane, F.,
and Strauss, J. F.
(1997)
Steroids
62,
5-9[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Sugawara, T.,
Kiriakidou, M.,
Mcallister, J. M.,
Kallen, C. B.,
and Strauss, J. F.
(1997)
Biochemistry
36,
7249-7255[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Caron, K. M.,
Ikeda, Y.,
Soo, S. C.,
Stocco, D. M.,
Parker, K. L.,
and Clark, B. J.
(1997)
Mol. Endocrinol.
11,
138-147[Abstract/Free Full Text]
|
| 15.
|
Sandhoff, T. W.,
Hales, D. B.,
Hales, K. H.,
and Mclean, M. P.
(1998)
Endocrinology
139,
4820-4831[Abstract/Free Full Text]
|
| 16.
|
Rust, W.,
Stedronsky, K.,
Tillmann, G.,
Morley, S.,
Walther, N.,
and Ivell, R.
(1998)
J. Mol. Endocrinol.
21,
189-200[Abstract]
|
| 17.
|
Morohash, K.,
Zanger, U. M.,
Honda, S.,
Hara, M.,
Waterman, M. R.,
and Omura, T.
(1993)
Mol. Endocrinol.
7,
1196-1204[Abstract/Free Full Text]
|
| 18.
|
Parker, K. L.,
and Schimmer, B. P.
(1997)
Endocr. Rev.
18,
361-377[Abstract/Free Full Text]
|
| 19.
|
Wooton-Kee, C. R.,
and Clark, B. J.
(2000)
Endocrinology
141,
1345-1355[Abstract/Free Full Text]
|
| 20.
|
Silverman, E.,
Eimerl, S.,
and Orly, J.
(1999)
J. Biol. Chem.
274,
17987-17996[Abstract/Free Full Text]
|
| 21.
|
Gyles, S. L.,
Burns, C. J.,
Whitehouse, B. J.,
Sugden, D.,
Marsh, P. J.,
Persaud, S. J.,
and Jones, P. M.
(2001)
J. Biol. Chem.
276,
34888-34895[Abstract/Free Full Text]
|
| 22.
|
Aesoy, R.,
Mellgren, G.,
Morohashi, K.,
and Lund, J.
(2002)
Endocrinology
144,
295-303
|
| 23.
|
Yu, R. N.,
Achermann, J. C.,
Ito, M.,
and Jameson, J. L.
(1998)
Trends Endocrinol. Metab.
5,
169-175
|
| 24.
|
Lalli, E.,
and Sassone-Corsi, P.
(1999)
Curr. Opin. Endocrinol. Diabetes
6,
185-190
|
| 25.
|
Zazopoulos, E.,
Lalli, E.,
Stocco, D.,
and Sassone-Corsi, P.
(1997)
Nature
390,
311-315[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Tamai, K. T.,
Monaco, L.,
Alastalo, T. P.,
Lalli, E.,
Parvinen, M.,
and Sassone-Corsi, P.
(1996)
Mol. Endocrinol.
10,
1561-1569[Abstract/Free Full Text]
|
| 27.
|
Python, C. P.,
Rossier, M. F.,
Vallotton, M. B.,
and Capponi, A. M.
(1993)
Endocrinology
132,
1489-1496[Abstract/Free Full Text]
|
| 28.
|
Elliott, M. E.,
and Goodfriend, T. L.
(1984)
Biochem. Pharmacol.
33,
1519-1524[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Tian, Y.,
Smith, R. D.,
Balla, T.,
and Catt, K. J.
(1998)
Endocrinology
139,
1801-1809[Abstract/Free Full Text]
|
| 30.
|
Cherradi, N.,
and Capponi, A. M.
(1998)
Trends Endocrinol. Metab.
9,
412-418[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Cherradi, N.,
Brandenburger, Y.,
and Capponi, A. M.
(1998)
Eur. J. Endocrinol.
139,
249-256[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Shibata, H.,
Ikeda, Y.,
Mukai, T.,
Morohashi, K.,
Kurihara, I.,
Ando, T.,
Suzuki, T.,
Kobayashi, S.,
Murai, M.,
Saito, I.,
and Saruta, T.
(2001)
Mol. Genet. Metab.
74,
206-216[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Hanley, N. A.,
Rainey, W. E.,
Wilson, D. I.,
Ball, S. G.,
and Parker, K. L.
(2001)
Mol. Endocrinol.
15,
57-68[Abstract/Free Full Text]
|
| 34.
|
Lalli, E.,
Melner, M. H.,
Stocco, D. M.,
and SassoneCorsi, P.
(1998)
Endocrinology
139,
4237-4243[Abstract/Free Full Text]
|
| 35.
|
Lalli, E.,
Ohe, K.,
Hindelang, C.,
and Sassone-Corsi, P.
(2000)
Mol. Cell. Biol.
20,
4910-4921[Abstract/Free Full Text]
|
| 36.
|
Muscatelli, F.,
Strom, T. M.,
Walker, A. P.,
Zanaria, E.,
Recan, D.,
Meindl, A.,
Bardoni, B.,
Guioli, S.,
Zehetner, G.,
and Rabl, W.
(1994)
Nature
372,
672-676[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Lalli, E.,
Bardoni, B.,
Zazopoulos, E.,
Wurtz, J. M.,
Strom, T. M.,
Moras, D.,
and Sassone-Corsi, P.
(1997)
Mol. Endocrinol.
11,
1950-1960[Abstract/Free Full Text]
|
| 38.
|
Das, S.,
Maizels, E. T.,
DeManno, D., St,
Clair, E.,
Adam, S. A.,
and Hunzicker-Dunn, M.
(1996)
Endocrinology
137,
967-974[Abstract]
|
| 39.
|
Tai, C. J.,
Kang, S. K.,
Tzengm, C. R.,
and Leung, P. C.
(2001)
Endocrinology
142,
1554-1560[Abstract/Free Full Text]
|
| 40.
|
Chabre, O.,
Cornillon, F.,
Bottari, S. P.,
Chambaz, E.,
and Vilgrain, I.
(1995)
Endocrinology
136,
956-964[Abstract]
|
| 41.
|
Cote, M.,
Muyldermans, J.,
Chouinard, L.,
and Gallo-Payet, N.
(1998)
Endocr. Res.
24,
415-419[Medline]
[Order article via Infotrieve]
|
| 42.
|
Babu, P. S.,
Bavers, D. L.,
Beuschlein, F.,
Shah, S.,
Jeffs, B.,
Jameson, J. L.,
and Hammer, G. D.
(2002)
Endocrinology
143,
665-673[Abstract/Free Full Text]
|
| 43.
|
Hosokawa, K.,
Dantes, A.,
SchereLevy, C.,
Barash, A.,
Yoshida, Y.,
Kotsuji, F.,
Vlodavsky, I.,
and Amsterdam, A.
(1998)
Endocrinology
139,
4679-4687[Abstract/Free Full Text]
|
| 44.
|
Sugawara, T.,
Holt, J. A.,
Kiriakidou, M.,
and Strauss, J. F.
(1996)
Biochemistry
35,
9052-9059[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Sugawara, T.,
Saito, M.,
and Fujimoto, S.
(2000)
Endocrinology
141,
2895-2903[Abstract/Free Full Text]
|
| 46.
|
Hammer, G. D.,
Krylova, I.,
Zhang, Y.,
Darimont, B. D.,
Simpson, K.,
Weigel, N. L.,
and Ingraham, H. A.
(1999)
Mol. Cell
3,
521-526[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Babu, P. S.,
Bavers, D. L.,
Shah, S.,
and Hammer, G. D.
(2000)
Endocr. Res.
26,
985-994[Medline]
[Order article via Infotrieve]
|
| 48.
|
Ito, M., Yu, R.,
and Jameson, J. L.
(1997)
Mol. Cell. Biol.
17,
1476-1483[Abstract]
|
| 49.
|
Crawford, P. A.,
Dorn, C.,
Sadovsky, Y.,
and Milbrandt, J.
(1998)
Mol. Cell. Biol.
18,
2949-2956[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Lymperopoulos, G. Rengo, C. Zincarelli, J. Kim, S. Soltys, and W. J. Koch
An adrenal {beta}-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo
PNAS,
April 7, 2009;
106(14):
5825 - 5830.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. R. Manna, M. T. Dyson, Y. Jo, and D. M. Stocco
Role of Dosage-Sensitive Sex Reversal, Adrenal Hypoplasia Congenita, Critical Region on the X Chromosome, Gene 1 in Protein Kinase A- and Protein Kinase C-Mediated Regulation of the Steroidogenic Acute Regulatory Protein Expression in Mouse Leydig Tumor Cells: Mechanism of Action
Endocrinology,
January 1, 2009;
150(1):
187 - 199.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Sirianni, A. Chimento, R. Malivindi, I. Mazzitelli, S. Ando, and V. Pezzi
Insulin-Like Growth Factor-I, Regulating Aromatase Expression through Steroidogenic Factor 1, Supports Estrogen-Dependent Tumor Leydig Cell Proliferation
Cancer Res.,
September 1, 2007;
67(17):
8368 - 8377.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. R Manna, Y. Jo, and D. M Stocco
Regulation of Leydig cell steroidogenesis by extracellular signal-regulated kinase 1/2: role of protein kinase A and protein kinase C signaling
J. Endocrinol.,
April 1, 2007;
193(1):
53 - 63.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. M. Gummow, J. O. Scheys, V. R. Cancelli, and G. D. Hammer
Reciprocal Regulation of a Glucocorticoid Receptor-Steroidogenic Factor-1 Transcription Complex on the Dax-1 Promoter by Glucocorticoids and Adrenocorticotropic Hormone in the Adrenal Cortex
Mol. Endocrinol.,
November 1, 2006;
20(11):
2711 - 2723.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J Casal, V. J P Sinclair, A. M Capponi, J. Nicod, U. Huynh-Do, and P. Ferrari
A novel mutation in the steroidogenic acute regulatory protein gene promoter leading to reduced promoter activity.
J. Mol. Endocrinol.,
August 1, 2006;
37(1):
71 - 80.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. R Manna, S. P Chandrala, Y. Jo, and D. M Stocco
cAMP-independent signaling regulates steroidogenesis in mouse Leydig cells in the absence of StAR phosphorylation.
J. Mol. Endocrinol.,
August 1, 2006;
37(1):
81 - 95.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Inagaki, F. Otsuka, J. Suzuki, Y. Kano, M. Takeda, T. Miyoshi, H. Otani, Y. Mimura, T. Ogura, and H. Makino
Involvement of Bone Morphogenetic Protein-6 in Differential Regulation of Aldosterone Production by Angiotensin II and Potassium in Human Adrenocortical Cells
Endocrinology,
June 1, 2006;
147(6):
2681 - 2689.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Ragazzon, A.-M. Lefrancois-Martinez, P. Val, I. Sahut-Barnola, C. Tournaire, C. Chambon, J.-L. Gachancard-Bouya, R.-J. Begue, G. Veyssiere, and A. Martinez
Adrenocorticotropin-Dependent Changes in SF-1/DAX-1 Ratio Influence Steroidogenic Genes Expression in a Novel Model of Glucocorticoid-Producing Adrenocortical Cell Lines Derived from Targeted Tumorigenesis
Endocrinology,
April 1, 2006;
147(4):
1805 - 1818.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-G. LeHoux and A. Lefebvre
Novel protein kinase C-epsilon inhibits human CYP11B2 gene expression through ERK1/2 signalling pathway and JunB
J. Mol. Endocrinol.,
February 1, 2006;
36(1):
51 - 64.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. R. Manna, S. P. Chandrala, S. R. King, Y. Jo, R. Counis, I. T. Huhtaniemi, and D. M. Stocco
Molecular Mechanisms of Insulin-like Growth Factor-I Mediated Regulation of the Steroidogenic Acute Regulatory Protein in Mouse Leydig Cells
Mol. Endocrinol.,
February 1, 2006;
20(2):
362 - 378.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. F. Clem and B. J. Clark
Association of the mSin3A-Histone Deacetylase 1/2 Corepressor Complex with the Mouse Steroidogenic Acute Regulatory Protein Gene
Mol. Endocrinol.,
January 1, 2006;
20(1):
100 - 113.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Wang, P. Paradis, A. Aries, H. Komati, C. Lefebvre, H. Wang, and M. Nemer
Convergence of Protein Kinase C and JAK-STAT Signaling on Transcription Factor GATA-4
Mol. Cell. Biol.,
November 15, 2005;
25(22):
9829 - 9844.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-C. Battista, M. Otis, M. Cote, A. Laforest, M. Peter, E. Lalli, and N. Gallo-Payet
Extracellular Matrix and Hormones Modulate DAX-1 Localization in the Human Fetal Adrenal Gland
J. Clin. Endocrinol. Metab.,
September 1, 2005;
90(9):
5426 - 5431.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F.-Q. Yu, C.-S. Han, W. Yang, X. Jin, Z.-Y. Hu, and Y.-X. Liu
Activation of the p38 MAPK pathway by follicle-stimulating hormone regulates steroidogenesis in granulosa cells differentially
J. Endocrinol.,
July 1, 2005;
186(1):
85 - 96.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. F. Buholzer, J.-F. Arrighi, S. Abraham, V. Piguet, A. M. Capponi, and A. J. Casal
Chicken Ovalbumin Upstream Promoter-Transcription Factor Is a Negative Regulator of Steroidogenesis in Bovine Adrenal Glomerulosa Cells
Mol. Endocrinol.,
January 1, 2005;
19(1):
65 - 75.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Jo and D. M. Stocco
Regulation of Steroidogenesis and Steroidogenic Acute Regulatory Protein in R2C Cells by DAX-1 (Dosage-Sensitive Sex Reversal, Adrenal Hypoplasia Congenita, Critical Region on the X Chromosome, Gene-1)
Endocrinology,
December 1, 2004;
145(12):
5629 - 5637.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. SPAT and L. HUNYADY
Control of Aldosterone Secretion: A Model for Convergence in Cellular Signaling Pathways
Physiol Rev,
April 1, 2004;
84(2):
489 - 539.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gambaryan, E. Butt, K. Marcus, M. Glazova, A. Palmetshofer, G. Guillon, and A. Smolenski
cGMP-dependent Protein Kinase Type II Regulates Basal Level of Aldosterone Production by Zona Glomerulosa Cells without Increasing Expression of the Steroidogenic Acute Regulatory Protein Gene
J. Biol. Chem.,
August 8, 2003;
278(32):
29640 - 29648.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Lalli and P. Sassone-Corsi
DAX-1, an Unusual Orphan Receptor at the Crossroads of Steroidogenic Function and Sexual Differentiation
Mol. Endocrinol.,
August 1, 2003;
17(8):
1445 - 1453.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yazawa, T. Mizutani, K. Yamada, H. Kawata, T. Sekiguchi, M. Yoshino, T. Kajitani, Z. Shou, and K. Miyamoto
Involvement of Cyclic Adenosine 5'-Monophosphate Response Element-Binding Protein, Steroidogenic Factor 1, and Dax-1 in the Regulation of Gonadotropin-Inducible Ovarian Transcription Factor 1 Gene Expression by Follicle-Stimulating Hormone in Ovarian Granulosa Cells
Endocrinology,
May 1, 2003;
144(5):
1920 - 1930.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|